Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor

Advances in Experimental Medicine and Biology

Volumn 394, Issue , 1996, Pages 279-289

  Freimuth, William W ^b  

^a PFIZER INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DELAVIRDINE; DIDANOSINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADULT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME INHIBITION; FATIGUE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; MAJOR CLINICAL STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0029928409     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4757-9209-6_25     Document Type: Conference Paper

References (42)

1. Romero DL, Busso M, Tan CK et al. Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 1991;88:8806-8810.
2. Vasudevachari MB, Battista C, Lane HC, et al. Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors Virology 1992;190:269-277.
3. Dueweke TJ, Kezdy FJ, Waszak GA, et al. The binding of a novel bisheteroarylpiperazine mediates inhibition of HIV-1 reverse transcnptase. J Biol Chem 1993;267:27-30.
4. Romero DL, Morge RA, Genin MJ et al. Bis(heleroaryl)piperazme (BHAP) reverse transcriptase inhibitors: Structure-activity relationships of novel substituted indole analogues and identification of U90152S, a second generation clinical candidate. J Med Chem 1993,36:1505-1508.
5. Dueweke TJ, Poppe SM, Romero DL et al. U-90152S, a potent inhibitor of human deficiency virus type 1 replication. Antimicrob Agents Chemother 1993;37:1127-1131.
6. Althaus IW, Chou JJ, Gonzales AJ, et al. Kinetic studies with the non-nucleoside human immunodeficiency virus type-1 reverse transcriptase inhibitor U-90152E. Biochem Pharmacol 1994;47:2017-2028.
7. Wathen LK, Freimuth WW, Batts DH et al. Phenotypic and genotypic characterization of HIV-1 viral isolates from patients treated with combined AZT and delavirdine mesylate (DLV) therapy. Third International Workshop on HIV and Drug Resistance. Kauai, Hawaii, August 2-5, 1994, page 42.
8. Freimuth B, Davey R, Batts D, et al. Phase II clinical trials of delavirdine mesylate combination therapy Abstract 512 B, Vol. 2, Page 59. Tenth International Conference on AIDS, Yokohama, Japan, August 7-12, 1994.
9. Nottet HSLM, Oteman MHT, Visser MR et al. Anti-HIV-1 activities of novel non-nucleoside reverse transcriptase inhibitors. J Antimicrob Agents Chemother (letter) 1994;33:366-368.
10. Balzarini J, Karlsson A, Perez-Perez MJ et al. Knocking-out concentrations of HIV-1 specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus. Virology 1993;19:6576-585.
11. Chong KT, Pagano PJ, Hinshaw RR. Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3′-azido-3′-deoxythymidine or 2′, 3′ -dideoxyctidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro. Antimicrob Agents Chemother 1994;38:288-293.
12. Chong KT and Pagano PJ. Antiviral effect of convergent vs divergent drug combination on HIV-1 spread in vitro. Abstract PA0314, Vol 2, Page 108. Tenth International Conference on AIDS, Yokohama, Japan, August 7-12, 1994.
13. Pagano PJ and Chong KT. In vitro inhibition of human immunodeficiency virus type 1 by combination of delavirdine with protease inhibitor U-75875 or alpha interferon. J Infect Dis 1995;171:61-67.
14. Chong KT, Pagano PJ, and Hinshaw RR. Synergistic inhibition of human immunodeficiency virus in vitro by U-90152 (bisheteroarylpiperazine) and protease inhibitor, U-75875. IXth International Conference on AIDS Berlin, Germany, June 7-11, 1993.
15. Dueweke TJ, Pushkarskaya T, Poppe SM et al. A mutation in reverse transcriptase of bisheteroaryl piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc Natl Acad Sci USA 1993;90:4713-4717.
16. Byrnes VW, Sardana VV, Schleif WA et al. Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors Antimicrob Agents Chemother 1993;37:1576-1579.
17. Larder BA. Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. J Gen Virol 1994;75:951-957.
18. De ClercQ E. HIV resistance to reverse transcriptase inhibitors Biochem Pharmacol 1994;47:155-169.
19. Sharma SK, Fan N, Evan DB et al. Probing the mechanism for the in vitro drug resistance-sensitization mediated by the proline to leucine change at 236 of HIV-1 reverse transcriptase. Third International Workshop on HIV Drug Resistance, Kauai, Hawaii, page 41, August 2-5, 1994.
20. Smerdon SJ, Jager J, Kohlstaedt LA et al. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc Natl Acad Sci 1994;91:3911-3915.
21. Spence RA, Kati WM, Anderson KS et al. Mechanism of inhibition of HIV-1 reverse transcriptase inhibitors Science 1995;267:988-993.
22. Balzarini J, Karlsson A, Perez-Perez MJ et al. Treatment of human immunodeficiency virus type-1 (HIV-1)-infected cells with combinations of HIV-1 specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. J Virol 1993;67(9):5353-5359.
23. Cox SR, Batts DH, Ward P, et al. Escalating single and multiple dose safety, tolerance and pharmacokinetics (PK) of delavirdine mesylate (DLV, U-90152S) in normal volunteers. First National Conference on Human Retroviruses and Related Infections. Abstact No. 562, Washington DC, December 12-16, 1993.
24. Batts DH, Freimuth WW, Cox SR et al. Open-label escalating multiple-dose study of the safety, tolerance and pharmacokinetics of oral U-90152S (delavirdine, DLV) in HIV-1 infected males and females who are maintained on a stable dose of AZT. First National Conference on Human Retroviruses and Related Infections. Abstract No. 564, Washington DC, December 12-16, 1993.
25. Voorman RL, Maio SM and Wang X. Mechanism-based inactivation of rat and human cytochrome P450 3A by delavirdine. 9th International Conference on Cytochrome P450. Abstract, Zurich, Switzerland, July 23-27, 1995.
26. + patients. 34th Interscience Conf. on Antimicrobial Agents and Chemotherapy, Abstract No A52, p. 82, Orlando, FL, October 4-7, 1994.
27. Cox SR, Della-Colletta AA and Freimuth WW. Single-dose pharmacokinetic (PK) studies with delavirdine (DLV) mesylate: Dose proportionality and effects of food and antacid. 34th Interscience Conf. on Antimicrobial Agents and Chemotherapy, Abstract No. A54, p. 82, Orlando, FL, October 4-7, 1994.
28. + patients. 35th Interscience Conf. on Antimicrobial Agents and Chemotherapy, Abstract, San Francisco, CA, September 17-20, 1995.
29. + patients. 35th Interscience Conf on Antimicrobial Agents and Chemotherapy, Abstract, San Francisco, CA, September 17-20, 1995.
30. Morse GD, Cox SR, DeRemer MF et al. ZDV (ZDV) pharmacokinetics during an escalating multiple-dose study of delavirdine (DLV) mesylate. 34th Interscience Conf. on Antimicrobial Agents and Chemotherapy, Abstract No. 1156, p.132, Orlando, FL, October 4-7, 1994.
31. Cox SR, Anderson RD, Driver M et al. Effect of fluconazole (FLU) on the clinical pharmacokinetics of delavirdine (DLV) Abstract PB0284, Vol 1, Page 214. Tenth International Conference on AIDS Yokohama, Japan, August 7-12, 1994.
32. Cox SR, Borin MT, Driver MR et al. Effect of clarithromycin (CLAR) on the steady-state pharmacokinetics (PK) of delavirdine (DLV) in HIV-1 patients. Second National Conference on Human Retroviruses and Related Infections. Abstract No 487, Washington DC, January 31 - February 3,1995.
33. + patients. 34th Interscience Conf. on Antimicrobial Agents and Chemotherapy, Abstract No A48, p. 81, Orlando, FL, October 4-7, 1994.
34. + patients. 34th Interscience Conf on Antimicrobial Agents and Chemotherapy, Abstract No A50, p 82, Orlando, FL, October 4-7, 1994.
35. Davey RT, Chaitt DG, Freimuth WW et al. A randomized phase I/II trial of delavirdine (U-90152S) compared to combination nucleoside therapy in HIV-1 infection. Second National Conference on Human Retroviruses and Relation Infections, Washington, D.C., January 29 - February 2, 1995. Abstract No 267.
36. Dewar RL, Highbarger HC, Sarmiento MD et al. Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. J Infect Dis 1994;170:1172-1179.
37. Reichman RC, Morse GD, Demeter LM et al. Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. J Infect Dis 1995;171:297-304.
38. Richman DD, Havlir D, Corbeil J et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994;68:1660-1666.
39. De Jong MD, Loewenthal M, Boucher CAB et al. Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity. J Infect Dis 1994;169:1346-1350.
40. Havlir D, Cheeseman SH, Mc Laughlin M et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995,171:537-545.
41. Saag M, Emmi EA, Laskin OL et al. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. N Eng J Med 1993;329:1065-1072.
42. Combination therapy with zidovudine prevents selection of human immunodeficiency virus type I variants expressing high-level resistance to a nonnucleoside reverse transcriptase inhibitor. J Infect Dis 1995;171:1159-1165.